News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Marinomed Biotech AG with important progress for Carragelose in 2024
Marinomed Biotech AG enrolls first patient in clinical study for Carragelose eye drops and receives patents in Singapore, South Korea, and Brazil, strengthening its IP portfolio. The company plans to launch Carragelose eye drops and nasal spray in 2024, targeting allergy and eye care markets -